Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing
Study Details
Study Description
Brief Summary
This is a phase 2 trial seeking to define the safety and activity of gemcitabine, cisplatin, plus nivolumab as neoadjuvant therapy in patients with muscle-invasive bladder cancer and to define the role of clinical complete response in predicting benefit in patients opting to avoid cystectomy.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Gemcitabine, Cisplatin and Nivolumab Combination Therapy: Nivolumab 360mg IV, Gemcitabine 100mg/m^2 IV ,Cisplatin 70mg/m^2 IV for four 21-day cycles. At restaging, subjects with cT0 or cTa status may undergo cystectomy or continue maintenance Nivolumab 240mg IV for up to 8 14-day cycles. Subjects with > cTa status will undergo cystectomy. |
Drug: Nivolumab
Nivolumab 360mg will be administered on Day 1 of each 21 day cycle for four 21-day cycles. Based on response and a balanced patient-physician discussion, subjects may receive nivolumab 240 mg for 8 cycles (cycle = 14 days).
Other Names:
Drug: Gemcitabine
Gemcitabine 1000mg/m^2 will be administered on Days 1 and 8 for four 21-day cycles.
Other Names:
Drug: Cisplatin
Cisplatin 70mg^m2 will be administered on Day 1 for four 21-day cycles.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Determine the clinical complete response rate (cT0 or cTa) with gemcitabine, cisplatin, plus nivolumab [24 months]
Clinical complete response rate will be defined as cT0 or cTa disease after gemcitabine, cisplatin, plus nivolumab.
- Determine the ability of clinical complete response (cT0 or cTa) to predict benefit from treatment. [24 months]
Benefit will be defined as a pathologic complete response (<pT1) in patients undergoing cystectomy and 2 year metastasis-free in patients pursuing surveillance
Secondary Outcome Measures
- Assess Adverse Events [24 months]
Assess adverse events according to the NCI Common Terminology Criteria for Adverse Events (NCI CTCAE) v4
- Bladder intact overall survival [24 Months]
Bladder-intact overall survival is defined as the time from initiation of treatment until death or cystectomy
- Recurrence-free survival [24 months]
Recurrence-free survival is defined as the time from initiation of treatment to death or recurrence, depending on which occurs first
- Pathologic complete response rate in patients undergoing cystectomy [24 Months]
Pathologic complete response rate in patients undergoing radical cystectomy is defined as the proportion of patients with <pT1
- Determine the association between a prespecified panel of genomic biomarkers and benefit from treatment in patients achieving a clinical complete response. [24 months]
Benefit will be defined as a pathologic complete response (p<T1) in patients undergoing cystectomy and 2 years metastasis-free in patients pursuing surveillance
Eligibility Criteria
Criteria
Inclusion Criteria:
-
ECOG Performance Status of ≤ 1 within 28 days prior to registration.
-
Histological evidence of clinically localized muscle-invasive urothelial cancer of the bladder (i.e., ct2-4n0m0). candidate for cystectomy as per treating physician.
-
Demonstrate adequate organ function per listed criteria:
-
Absolute Neutrophil Count (ANC): ≥ 1.5 x 10^9/L
-
Hemoglobin (Hgb): ≥ 9 g/dL
-
Platelets: ≥ 100 x 10^9/L
-
Calculated creatinine clearance: Creatinine ≤ 1.5 or creatinine clearance ≥ 60 mL/min
-
Bilirubin: ≤ 1.5 × upper limit of normal (ULN) (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL)
-
Aspartate aminotransferase (AST) : ≤ 3 × ULN
-
Alanine aminotransferase (ALT) : ≤ 3 × ULN
-
All subjects must have adequate archival tissue identified at screening (i.e., at least 15 unstained slides or paraffin block). Subjects without available archival tissue must be discussed with the sponsor-investigator.
-
Women of childbearing potential must have a negative serum or urine pregnancy within 7 days prior to C1D1. NOTE: "Women of childbearing potential" is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 62 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL.
NOTE: Women of childbearing potential (WOCBP) receiving nivolumab must be willing to abstain from heterosexual intercourse or to use 2 forms of effective methods of contraception from the time of informed consent to 5 months after the last dose of nivolumab or for the timeframe outlined per package insert for chemotherapy. This timeframe also applies to breastfeeding. The two contraception methods can be comprised of two barrier methods, or a barrier method plus a hormonal method. Male subjects capable of fathering a child that are sexually active with partners of childbearing potential must be willing to abstain from heterosexual intercourse or to use 2 forms of effective methods of contraception from the time of informed consent to the timeframe outlined per package insert for chemotherapy. Contraception is not required for nivolumab. The timeframes described in the previous 2 sentences apply to sperm donation. Two contraception methods can be comprised of two barrier methods, or a barrier method plus a hormonal method.
Exclusion Criteria:
-
Prior treatment with systemic chemotherapy for muscle-invasive urothelial cancer of the bladder
-
Active infection requiring systemic therapy
-
Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).
-
Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results.
-
Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured.
-
Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
-
Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
-
Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways.
-
Grade ≥ 2 neuropathy (NCI CTCAE version 4).
-
Prior radiation therapy for bladder cancer
-
Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (RNA) or hepatitis C antibody (HCV antibody) indicating acute or chronic infection.
-
Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
-
Evidence of interstitial lung disease or active, non-infectious pneumonitis.
-
Solid organ or allogeneic stem cell transplant
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | City of Hope | Duarte | California | United States | 91010 |
| 2 | Univerity of Southern California | Los Angeles | California | United States | 90033 |
| 3 | Icahn School of Medicine: Tisch Cancer Institute at Mount Sinai Medical Center | New York | New York | United States | 10029 |
| 4 | Oregon Health & Science University | Portland | Oregon | United States | 97239 |
| 5 | Penn Medicine Abramson Cancer Center | Philadelphia | Pennsylvania | United States | 19104 |
| 6 | Huntsman Cancer Institute University of Utah | Salt Lake City | Utah | United States | 84112 |
| 7 | University of Wisconsin | Madison | Wisconsin | United States | 53705 |
Sponsors and Collaborators
- Matthew Galsky
- Bristol-Myers Squibb
- Icahn School of Medicine at Mount Sinai
Investigators
- Principal Investigator: Matthew Galsky, MD, Icahn School of Medicine at Mount Sinai
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- HCRN GU16-257